LErafAON

DRUG2 trials

Sponsors

INSYS Therapeutics Inc

Conditions

Neoplasms

Phase 1

Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Solid Tumors

CompletedNCT00024661

INSYS Therapeutics IncNeoplasms

Start: 2001-03-31End: 2004-10-31Target: 30Updated: 2011-04-13

Study to Determine Maximum Tolerated Dose of LErafAON Combined With Radiotherapy in Patients With Advanced Malignancies

CompletedNCT00024648

INSYS Therapeutics IncNeoplasms

Start: 2001-03-31End: 2004-12-31Target: 25Updated: 2011-04-13